Categories
COVID-19 Government Guidelines Medical Equipments Medical Updates

Long Covid might teach us how to prevent Alzheimer’s

Researchers are uncovering links between viruses and brain diseases, which could point to a whole new approach to treatment.

Science is starting to uncover an unnerving fact about viruses: Some might affect our brains over the long haul. It came as a shock that SARS-CoV-2 can lead to lingering neurological problems — a post-viral syndrome we call long Covid. But the phenomenon might not be unique to this virus.

Scientists are finding links between common viruses such as influenza and brain diseases like multiple sclerosis, Parkinson’s, Alzheimer’s and ALS. Researchers are hoping that identifying a viral link might finally allow scientists to figure out what causes these mysterious, deadly ailments and develop new treatments.

A new study, published last week and summarized in Science, used a vast trove of electronic medical records to find thousands of people with neurodegenerative diseases and tease out correlations with 22 different kinds of infections. The biggest viral risk factor for dementia was encephalitis, which is an infection of the brain often caused by a mosquito or tick-borne disease. Other viruses tied to dementia included influenza, herpes zoster (shingles) and HPV.

Earlier studies had looked for specific viral links to Alzheimer’s and found correlations with herpes and some forms of HPV. And a study published last year showed that Epstein-Barr virus was necessary for developing MS. But scientists still haven’t figured out exactly what role the viruses play — whether they’re a direct trigger or have some peripheral role. Almost everyone on the planet carries Epstein-Barr virus, which causes mononucleosis, but only a tiny fraction ends up getting MS.

To better understand how viruses might be affecting the brain, I stopped by the National Institutes of Health to visit Avindra Nath, who is one of the few neurologists specializing in viruses — an interest he picked up after treating AIDS patients in the early 1980s. In 2014, he was the first neurologist to travel to Liberia to treat Ebola patients, and he said a fraction of those who recover suffer neurological symptoms similar to long Covid — especially chronic fatigue.

He told me that what really interests him are viruses that are embedded in our genetic codes — called endogenous retroviruses. They may have snuck in through a sexually transmitted virus that works itself into an embryo. These viruses are a source of genetic variation — and can add novel DNA to our genomes. Like mutations, these occasionally incur an advantage and spread through the population. About 8% of our genome is made of these embedded viruses.

Long Covid might teach us how to prevent Alzheimer’s

Nath’s interest in these started when he was treating a patient who had both HIV and ALS, and after taking antiretroviral drugs, the ALS disappeared. A series of human and animal studies convinced Nath that ALS might sometimes be triggered by an embedded virus called HERV-K.

Normally HERV-K is active during fetal development, so it may have spread through the human population because it does something useful in utero. But after we’re born, it normally shuts off (due to external chemical switches that bind to DNA).

Sometimes, he told me, these “off switches” fail, and one of these embedded viruses can become reactivated. That failure might be part of the cause of ALS. After years of animal studies, he started preliminary human trials assessing the effects of antiviral drugs on patients with ALS. He’s now planning a placebo-controlled clinical trial for drugs that he’s shown can suppress HERV-K.

He’s also studying the kinds of viruses we catch from the outside world. He thinks viruses are more likely to trigger brain diseases indirectly — not by getting directly into neurons, but by prompting inflammation. It’s the immune system’s response that causes the problem.

He’s now studying people with neurological problems following Covid infection — something that he estimates affected about 10% of people infected before vaccines were available and a much smaller fraction today. He said that at first he was very skeptical of claims that the virus hides out in the brain, but more recent studies have made him take it seriously, especially autopsy studies done by Dan Chertow at the NIH. It might be that those residual traces of the virus are causing persistent inflammation.

It’s possible that this has always been happening to some fraction of people who pick up common viruses. It’s just that it didn’t get all that much attention before the Covid pandemic. Nath said virology and neurology were two completely different worlds, and he was unique in trying to navigate both fields at the same time.

If viruses do indeed play a role in some of our most feared and costly diseases, that could point to a whole new approach to treatment and prevention. In the future, everyone might get vaccinated against Epstein-Barr virus as a protection against MS. And it may turn out that you can reduce your odds of getting Alzheimer’s disease by getting that shingles shot and a flu shot every year. If HPV adds to the risk, it could motivate the medical community to redouble its efforts to get that vaccine to more people.

Scientists could even eventually develop a universal, variant-proof Covid vaccine that would finally prevent the risk of long Covid.

Someday, people may look back at all the expensive drugs we tested for dementia and other brain diseases and wonder how we overlooked the benefits of cheap vaccines for so long.

Read more at-https://bit.ly/3kGNokj

Categories
COVID-19 Government Guidelines Medical Equipments Medical Updates Medicine & Health Techniques

Covid infection could damage foetuses of pregnant women: Study

Foetuses and placentas of pregnant women, especially those infected with COVID-19 at earlier points in the pandemic, were found to bear a greater risk of experiencing growth impairment or vascular lesions in organs and brain, according to a new research.

Foetuses and placentas of pregnant women, especially those infected with COVID-19 at earlier points in the pandemic, were found to bear a greater risk of experiencing growth impairment or vascular lesions in organs and brain, according to a new research.

According to the research, results demonstrate that the different strains of the virus that emerged during the pandemic led to varying degrees of damage, which was especially higher by those involving pre-Omicron variants. The detected placental lesions could potentially harm both development and health in some of the affected unborn children, the study said.

Using prenatal magnetic resonance imaging, a group of Medical University of Vienna, Austria, researchers examined the placentas and foetuses of women who tested positive for SARS-CoV-2 during pregnancy, the study said.

The research was published in the journal The Lancet Regional Health – Europe. While such damage occurs more infrequently and is less severe with the currently circulating Omicron sub-lineages, the study authors still advocate early detection measures for pregnant women who test positive for coronavirus.

Contrary to previous studies, in which SARS-CoV-2-related abnormalities were only identified postnatally and/or through histopathological procedures, the research team focused on prenatal imaging findings, the study said.

Using prenatal magnetic resonance imaging (MRI), 76 scans of placentas and foetuses of pregnant women were performed in the study: 38 following a confirmed SARS-CoV-2 infection (pre-Omicron or Omicron variants) and 38 in healthy control cases, the study said.

The study found that the placentas in both the pre-Omicron and the Omicron groups revealed abnormalities.

Covid infection could damage foetuses of pregnant women: Study

“Infections with pre-Omicron variants, such as Delta, led to significantly greater damage in the form of vascular events such as blood clots or bleeding than with the Omicron subvariants currently circulating through the population,” noted lead author Patric Kienast, outlining a key finding of the study.

The researchers attribute the varying extent of damage to the placenta caused by different virus strains to the fact that Omicron sub-lineages are less likely than their predecessors to result in severe cases, and to higher vaccination rates as the pandemic has progressed, the study said.

“In any case, our results showed that the two non-vaccinated study participants developed placental abnormalities following infection with SARS-CoV-2 Omicron, compared with just one out of six of the women who had received three doses of the vaccine,” confirmed senior author Gregor Kasprian.

Oxygen, nutrients and metabolic products are exchanged between mother and child in the placenta. Attached to the uterine wall, this organ forms such a strong barrier against the coronavirus that only 3 per cent or fewer of foetuses whose mothers test positive for SARS-CoV-2 are also infected, the study said.

But as the study shows, the placenta itself is not spared from complications caused by Covid-19. Subsequently, some unborn babies experience stunted growth or bleeding in the brain, the study said.

“This is why the placentas of pregnant women who have been infected with SARS-CoV-2 should be examined as soon as possible after testing positive using prenatal imaging techniques,” advised Daniela Prayer from Medical University of Vienna, citing the importance of scanning, particularly in the case of possible future coronavirus variants with mechanisms similar to Delta, for example.

By doing so, there is a chance to take measures to safeguard the health of the foetus in a worst case scenario, the study said.

Read more at-https://bit.ly/3XAOtZF

Categories
COVID-19 Government Guidelines Medical Equipments Medical Updates Medicine & Health

Panic attack: 3 tips to help someone who’s having a panic attack

Panic attacks can occur unexpectedly and have a significant impact on daily life. If you know someone who experiences frequent panic attacks, here are some tips to help them during an episode.

panic attack is a sudden and unexpected episode of intense fear or anxiety that can lead to physical as well as emotional discomfort. One having panic attack may feel they are going to die or have a heart attack. However, one experiencing it does not realise at that time that it’s not actually life threatening. Panic attacks have certain triggers and research suggests that it is your body’s natural fight-or-flight response to danger. A racing heartbeat, sweating, trembling, difficulty breathing, stomach cramps, dizziness, nausea or choking sensation are the common symptoms of panic attacks. One must get to the root of their panic attack and get in touch with an expert as it can affect one’s quality of life severely.

While a person tends to lose control during a panic attack and feels that all the physical symptoms are real, their near and dear ones can help them deal with it with the help of certain tips. Nutritionist Lovneet Batra in her recent Instagram post offered useful suggestions to help someone who’s having a panic attack.

“Panic attacks are sudden, intense surges of fear, panic, or anxiety. They are often extremely overwhelming, and they have physical as well as emotional symptoms. Panic attacks can occur unexpectedly and have a significant impact on your daily life. Due to the extreme nature of the symptoms, it is important to understand how to react and help when someone undergoes a panic attack, as they may feel as if they are dying during an episode. However, if a person present around them is able to help them, they might feel a little better or understood. Certain strategies and methods can help alleviate panic, ease the situation, and even stop the symptoms from getting worse. Each one of us must know how to react and offer help in such situations,” says Lovneet Batra.

Panic attack: 3 tips to help someone who's having a panic attack

If you know someone who experiences panic attacks, guide them with things you can do (and avoid doing) to help them at the moment.

“Many people hesitate in helping someone facing panic attacks mostly because they don’t know what to do and they fear making the situation even worse,” says Batra.

She shared the three things that can be helpful in such situations:

Give them water

Water has calming effect. In fact, drinking cold water triggers parasympathetic nervous system to keep a person calm. What can also be helpful is physical contact with water. So, either, keeping a person’s hand or feet in water or giving them cold water to put on the face around the neck that can help easing the anxiety.

Ask if they need to sit

Help them find a comfortable chair. Let them sit as this can have a literal grounding effect that can be healing and that can be calming for their anxiety.

Use grounding technique

A grounding technique uses all five senses in calming a person. A very common grounding technique is 5-4-3-2-1 where you can ask a person to list five things they see, four things they can touch, three things they hear, two things they can smell and one thing they can taste. This in fact helps in focussing their thoughts in those questions and helps you release anxiety.

Read more at-https://bit.ly/3Hkz8Wn

Categories
COVID-19 Government Guidelines Medical Equipments Medical Updates

Nonmelanoma skin cancer might be prevented with simple laser treatments: Study

According to new research, straightforward laser treatments to the skin may help to prevent the formation of these cancers. Basal cell carcinoma and squamous cell carcinoma, jointly known as keratinocyte carcinoma, are the most prevalent types of cancer identified in the United States.

New research indicates that simple laser treatments to the skin may help to prevent the development of basal cell carcinoma and squamous cell carcinoma, which are collectively known as keratinocyte carcinoma and are the most common types of cancer diagnosed in the United States. The work was conducted by a team of researchers from Massachusetts General Hospital, a founding member of Mass General Brigham. Published in Dermatologic Surgery, it reveals an easy-to-implement strategy to protect individuals’ skin health.

Nonablative fractional lasers (NAFL) deliver heat in a fractional manner that leaves it fully intact after treatment (unlike ablative fractional lasers that remove the top layer of skin), and they’re currently used to treat scars, sun-damaged skin, age spots, and more; however, their effectiveness for preventing skin damage is unknown.

To investigate, Mathew Avram, MD, JD, director of the Mass General Dermatology Laser & Cosmetic Center, and his colleagues studied patients who had been successfully treated for facial keratinocyte carcinoma in the past. Such patients have a 35% risk of experiencing a subsequent keratinocyte carcinoma within 3 years and a 50% risk within 5 years.

In the study, 43 patients received NAFL therapy and 52 served as controls and did not receive NAFL therapy. The rate of subsequent facial keratinocyte carcinoma development over an average follow-up of more than 6 years was 20.9% in NAFL-treated patients and 40.4% in controls, indicating that patients treated with NAFL had about half the risk.

Nonmelanoma skin cancer might be prevented with simple laser treatments: Study

When controlling for age, gender, and skin type, control patients were 2.65-times more likely to develop a new facial keratinocyte carcinoma than NAFL-treated patients. Also, among patients who developed a facial keratinocyte carcinoma, the time to development was significantly longer in patients treated with NAFL compared with untreated patients.

“These findings suggest that NAFL treatment may have an important role in protecting against subsequent keratinocyte carcinomas,” says Avram. “While the mechanism of NAFL’s protective effect is not completely understood, it is suspected that NAFL treatment reduces the overall burden of photo damaged keratinocytes and may promote a wound healing response, which gives healthy skin cells a selective advantage.”

Avram noted that additional studies are warranted to more critically assess the role of NAFL in skin cancer prevention, to reveal the duration of its protective effects, and to determine optimal treatment parameters. “Based on this research, it’s encouraged for patients to have nonablative laser treatments to help prevent skin cancer if they are at risk or notice abnormalities,” says Avram.

Read more at-https://bit.ly/3XE0Vas

Categories
COVID-19 Government Guidelines Medical Equipments Medical Updates Medicine & Health

Hospitalised patients’ infections may develop from their own bacteria: Study

Nearly 100,000 people die every year in U.S. hospitals of infections they develop after being admitted. But despite intense infection-control efforts, new strains of bacteria keep on emerging, seemingly out of nowhere, to sicken people in hospitals worldwide.

Hospitals have strict hygiene and sanitation protocols to protect patients from bacteria that rarely sicken healthy people but can be deadly for vulnerable patients already hospitalized with serious illnesses.

Nearly 100,000 people die every year in U.S. hospitals of infections they develop after being admitted. But despite intense infection-control efforts, new strains of bacteria keep on emerging, seemingly out of nowhere, to sicken people in hospitals worldwide.

Researchers at Washington University School of Medicine in St. Louis have found evidence pointing to an unexpected source of such bacteria: the hospitalized patients themselves. Studying mice, the researchers discovered that urinary tract infections (UTIs) can arise after sterile tubes, called catheters, are inserted into the urinary tract, even when no bacteria are detectable in the bladder beforehand. Such tubes are commonly used in hospitals to empty the bladders of people undergoing surgery. In the mice, inserting the tubes activated dormant Acinetobacter baumannii (A. baumannii)bacteria hidden in bladder cells, triggering them to emerge, multiply and cause UTIs, the researchers said.

The findings, published January 11 in Science Translational Medicine, suggest that screening patients for hidden reservoirs of dangerous bacteria could supplement infection-control efforts and help prevent deadly infections.

“You could sterilize the whole hospital, and you would still have new strains of A. baumannii popping up,” said co-senior author Mario Feldman, PhD, a professor of molecular microbiology. “Cleaning is just not enough, and nobody really knows why. This study shows that patients may be unwittingly carrying the bacteria into the hospital themselves, and that has implications for infection control. If someone has a planned surgery and is going to be catheterized, we could try to determine whether the patient is carrying the bacteria and cure that person of it before the surgery. Ideally, that would reduce the chances of developing one of these life-threatening infections.”

The findings, published January 11 in Science Translational Medicine, suggest that screening patients for hidden reservoirs of dangerous bacteria could supplement infection-control efforts and help prevent deadly infections.

Hospitalised patients' infections may develop from their own bacteria: Study

“You could sterilize the whole hospital, and you would still have new strains of A. baumannii popping up,” said co-senior author Mario Feldman, PhD, a professor of molecular microbiology. “Cleaning is just not enough, and nobody really knows why. This study shows that patients may be unwittingly carrying the bacteria into the hospital themselves, and that has implications for infection control. If someone has a planned surgery and is going to be catheterized, we could try to determine whether the patient is carrying the bacteria and cure that person of it before the surgery. Ideally, that would reduce the chances of developing one of these life-threatening infections.”

Feldman and Hultgren — along with co-first authors Jennie E. Hazen, a graduate student, and Gisela Di Venanzio, PhD, an instructor in molecular microbiology — investigated whether A. baumannii can hide inside cells like E. coli can. They studied mice with UTIs caused by A. baumannii. They used mice with weakened immune systems because, like people, healthy mice can fight off A. baumannii.

Once the infections had resolved and no bacteria were detected in the mice’s urine for two months, the researchers inserted catheters into the mice’s urinary tracts with a sterile technique. Within 24 hours, about half of the mice developed UTIs caused by the same strain of A. baumannii as the initial infection.

“The bacteria must have been there all along, hiding inside bladder cells until the catheter was introduced,” Hultgren said. “Catheterization induces inflammation, and inflammation causes the reservoir to activate, and the infection blooms.”

Since A. baumannii rarely causes symptoms in otherwise healthy people, many people who carry the bacteria may never know they’re infected, the researchers said. As part of this study, the researchers searched the scientific literature and discovered that about 2 pc of healthy people carry A. baumannii in their urine.

“I wouldn’t put much weight on the precise percentage, but I think we can say with certainty that some percentage of the population is walking around with A. baumannii,” Feldman said.

“As long as they’re basically healthy, it doesn’t cause any problems, but once they’re hospitalized, it’s a different matter. This changes how we think about infection control. We can start considering how to check if patients already have Acinetobacter before they receive certain types of treatment; how we can get rid of it; and if other bacteria that cause deadly outbreaks in hospitals, such as Klebsiella, hide in the body in the same way. That’s what we’re working on figuring out now.”

Read more at-https://bit.ly/3XvfvkG

Categories
COVID-19 Government Guidelines Medical Updates Medicine & Health

Is it flu or Covid-19? Experts on how to differentiate between the symptoms

Flu and Covid-19, both being respiratory illnesses, have a lot in common in terms of symptoms and way of transmission. Here’s how you can know the difference between their symptoms.

Flu and Covid-19, both being respiratory illnesses, have a lot in common in terms of symptoms like fever, cough, sore throat, difficulty breathing, and how they are transmitted – through cough, sneeze or touching an infected object. So, you may not initially know if you are suffering from flu or Covid-19. The best way to know for sure is to get tested without delay. The primary difference between the two is that the flu and Covid-19 are caused by difference viruses. Covid-19 is caused by the SARS-CoV-2, while influenza viruses are responsible for flu. Flu may cause severe symptoms in elderly while Covid-19 can lead to severe disease even in those who are not in vulnerable group. Covid can infect a greater number of people than flu and the symptom onset is slightly slower. Good thing is there is a vaccine for both the infections and one must get their shots to prevent these infections.

We spoke to experts on difference between flu and Covid-19 symptoms and here’s what they said.

“The flu and Covid-19 are both respiratory illnesses, but they are caused by different viruses. Symptoms of the flu and Covid-19 can be similar, such as fever, cough, and fatigue, but there are some key differences. The flu typically causes more severe symptoms in the elderly and people with underlying health conditions, whereas Covid-19 can cause severe illness in people of all ages,” says Dr Shalini Joshi, Senior Consultant-Internal Medicine, Fortis Hospital Bannerghatta Road, Bangalore.

Is it flu or Covid-19? Experts on how to differentiate between the symptoms

Different viruses

“Covid-19 and flu (Influenza) are contagious illnesses of the respiratory tract. They differ from each other in several aspects. These are caused by two different viruses, i.e., SARS CoV-2 and influenza virus, respectively,” says Dr Rohit Kumar Garg, Consultant, Department of Infectious Diseases, Amrita Hospital, Faridabad.

Loss of taste or smell

Dr Joshi says Covid-19 can cause loss of taste or smell, which is not a symptom of the flu.

“Although symptoms such as fever, cough, sore throat, body aches, headache, fatigue, vomiting, diarrhoea etc. are usual and common to both, COVID patients may also experience loss of smell, loss of taste,” says Dr Garg.

Symptom onset

“The time period from viral exposure to symptoms onset is shorter for flu (1-4 days) and somewhat longer for Covid (2–14 days). The exposed person starts spreading the SARS CoV-2 virus 2–3 days before symptoms onset, whereas in the flu, patients start spreading 1 day before symptoms,” says Dr Garg.

Which is more contagious?

“Patients remain infective for a longer duration after Covid than flu. SARS CoV-2 virus is more contagious than flu virus, i.e., it can infect many patients at a time, whereas only 1-2 patients at a time in case of flu,” says Dr Garg.

Symptoms and complications in Covid-19

“A Covid patient may also experience the formation of clot in blood vessels and cytokine release syndrome, in addition to other complications such as pneumonia, respiratory failure, multi-organ dysfunction, or sepsis etc. A Covid patient may experience symptoms such as cough, fatigue, shortness of breath, a high pulse rate, poor appetite, etc. for a long time after recovery from an acute illness,” says Dr Garg, adding, “SARS CoV-2 virus can cause serious complications even in healthy individuals, unlike the flu, which cause serious complications usually in patients with comorbid conditions.”

“It’s crucial to take the appropriate precautions to protect yourself and others from both viruses, the best way to prevent both is to get vaccinated, and practice good hygiene, such as washing your hands frequently and avoiding close contact with sick people. Flu (Influenza) is caused by a virus and most people recover on their own but it can lead to serious problems in high-risk patients. Therefore, we recommend yearly Influenza vaccination for elderly people, people living with chronic health diseases like diabetes, liver and kidney issues or weak immune systems. Consultation with a doctor is advised because the symptoms are quite similar. It is important to conduct appropriate tests for diagnosis and early treatment should be started by the health care professionals,” says Dr Shalini Joshi.

“There are specific antiviral treatments and vaccines for SARS CoV-2 and influenza viruses. Despite these differences, the key preventive strategies, i.e., social distancing, use of face masks, cough etiquettes, hand cleanliness, and vaccination, remain the same for both due to similarity in mode of transmission and route of infection, as well as the availability of effective vaccines against both of them, says Dr Rohit Kumar Garg.

Read more at-https://bit.ly/3iGkReb

Categories
COVID-19 Government Guidelines Medical Updates Medicine & Health

Long Covid symptoms fading for mild coronavirus infections, says new study

Long covid is defined as symptoms persisting or new symptoms appearing more than four weeks after initial infection. A new study reveals that most Long Covid symptoms that developed after a mild coronavirus infection lingered for several months but returned to normal within a year.

The effects of long Covid tend to resolve within a year of mild infection, with vaccinated people at lower risk of breathing difficulties compared with unvaccinated people, according to a study.

Researchers examined the health records of almost 2 million people in Israel who tested for Covid-19 over a 19-month period. Over 70 long Covid conditions were analyzed within a group of infected and matched uninfected members. They also compared conditions in vaccinated versus unvaccinated people.

Their study published in the BMJ medical journal found most symptoms that developed after a mild infection lingered for several months, but returned to normal within a year.

“The long Covid phenomenon has been feared and discussed since the beginning of the pandemic,” the researchers wrote. “This nationwide dataset of patients with mild Covid-19 suggests that mild disease does not lead to serious or chronic long term morbidity.”

Previous studies have indicated that vaccination tends to lead to milder cases of Covid infection and long Covid.

Long Covid symptoms fading for mild coronavirus infections

Long covid is defined as symptoms persisting or new symptoms appearing more than four weeks after initial infection. An estimated 1.5 million people in the UK, or 2.4% of the population, were suffering from long Covid symptoms in March. These include fatigue, shortness of breath, loss of smell, loss of taste and difficulty concentrating.

Some of the limitations of the study include incomplete measurement within the medical records, meaning the data might not fully reflect diagnoses and outcomes reported, according to the researchers.

“The general message that symptoms improve over time is encouraging,” said Peter Openshaw, professor of experimental medicine at Imperial College London, who was not part of the research team. “The study adds to the evidence that outcomes are improved by vaccination, even if vaccines don’t prevent viral transmission very well.”

Read more at-https://bit.ly/3k4LycJ

Categories
COVID-19 Government Guidelines Medical Updates Medicine & Health

Booster dose of Covid-19 increases resilience of antibody response: Study

The most recent study explains how Pfizer and Moderna mRNA boosters affect our Covid-19 antibodies’ ability to remain over time. The researchers found that all patients, including those who had recovered from a Covid-19 infection, developed more robust antibodies in response to a booster.

Recent research from the University of Virginia School of Medicine discussed the benefits of a Covid-19 booster vaccine dose. The most recent study clarifies how Pfizer and Moderna mRNA boosters influence the persistence of our Covid-19 antibodies. According to the researchers, a booster produced more durable antibodies in all individuals, including those who had recovered from a Covid-19 infection.

The researchers have published their latest findings in the scientific journal Annals of Allergy, Asthma & Immunology. “These results fit with other recent reports and indicate that booster shots enhance the durability of vaccine-elicited antibodies,” said senior researcher Jeffrey Wilson, MD, PhD, of UVA Health’s Division of Asthma, Allergy and Immunology.

Tracking Covid-19 antibodies: Wilson and his collaborators looked at antibody levels following a booster in 117 UVA employee volunteers and compared those results with the levels seen in 228 volunteers after their primary vaccination series. Antibody levels one week to 31 days after the primary series and booster were similar, but the boosted antibodies stuck around longer regardless of whether the person had had Covid-19.

“Our initial thought was that that booster would lead to higher antibody levels than the primary vaccine series, but that was not what we found,” said researcher Samuel Ailsworth, the first author of a new scientific paper outlining the findings. “Instead, we found that the booster led to longer-lasting antibodies.”

Antibody levels naturally decline over time after an infection or after vaccination, but higher levels are thought to be more protective. Thus, longer-lasting antibodies would be expected to provide more sustained immunity against severe Covid-19.

Booster dose of Covid-19 increases resilience of antibody response

The researchers found that the antibodies generated by the Moderna booster proved longer lasting than those generated by the Pfizer booster. Moderna’s antibody levels exceeded Pfizer’s out to five months, the end of the study period. Although the findings were statistically significant, Wilson notes that both mRNA vaccine boosters provide enhanced and fairly similar levels of protection against Covid-19 in recently published large epidemiologic studies. Because the frequency of Covid-19 infections in the community was relatively high when the boosters were being given, the authors also studied the effect of COVID-19 infection on antibody levels. The findings suggest that the “enhanced antibody durability observed after booster vaccination was not explained by hybrid immunity,” the researchers report in their paper.

The new results are the latest from Wilson’s team tracking the antibody response to the Covid-19 vaccines over time. The researchers previously found that after the primary vaccination series the antibodies generated by Pfizer’s Covid-19 vaccine rose more slowly and declined more quickly than those generated by the Moderna vaccine. That study also found that older recipients of the Pfizer vaccine generated fewer antibodies than did younger recipients – but this wasn’t the case for Moderna, where age did not appear to be a factor.

In the latest results, younger booster recipients initially generated more antibodies than did older recipients, but this difference disappeared with time. Wilson notes that this study adds to the accumulating evidence that boosters are important in protecting the community from Covid-19. “Although only about half of the U.S. population that is eligible for a booster has received one, it is increasingly clear that boosters enhance the protection that is conferred by the primary series mRNA vaccines alone,” he said.

Read more at-https://bit.ly/3Ie0a3E

Categories
COVID-19 Government Guidelines Medical Equipments Medical Updates Medicine & Health

Cancer vaccine hunt makes progress, finally

A small study shows promise in deploying mRNA technology against melanoma, but fighting tumors is vastly more complex than tackling Covid.

The long-awaited cancer vaccine revolution is getting a little closer to reality. New data from Moderna Inc. and Merck & Co. suggest that after decades of failures, researchers are finally figuring out the right way to design a vaccine that can teach immune cells how to recognize and combat tumors.

Earlier this month, the companies said that when used in concert with Merck’s cancer immunotherapy Keytruda, Moderna’s mRNA cancer vaccine reduced the risk of certain skin cancers from returning or patient deaths by 44% compared with Keytruda alone.

That number justly generated a lot of excitement. It’s the first time an mRNA-based cancer vaccine has proven itself in a randomized study, and with an unambiguously positive outcome. If that result holds up in larger trials, it would be a huge advance both for the mRNA technology behind Covid vaccines and for the field of cancer vaccines in general.

But there are a lot of steps between achieving early, positive data for a subset of melanoma patients and developing a widely accessible, cost-effective treatment. Among the more daunting challenges: The vaccine needs to be tailored to the genetic makeup of an individual patient’s tumors.

The study was small, enrolling just 157 people at high risk of their late-stage skin cancer returning. (Moderna and Merck have yet to make available the full dataset, though they plan to do so at an upcoming conference.) Still, even if the results are slightly less dramatic in a bigger study, the vaccine could make a difference for patients. “That would be a substantial change,” translating into long-term remissions, says Julie Bauman, director of the George Washington University Cancer Center. Bauman led an earlier study of Moderna’s cancer vaccine.

The study enrolled melanoma patients who had undergone surgery to remove any signs of their cancer. Unlike vaccines the public is used to taking — mass-produced shots that aim to prevent people from catching a contagious disease like the flu or polio, Moderna’s cancer vaccine instead is intended to keep the disease from returning. It does that by training immune cells to recognize as dangerous proteins found on a patient’s own tumor cells.

The hope was that the vaccine would amplify the already substantial benefit of Keytruda, which blocks a method that cancer cells use to hide from the immune system. Amazingly, the combination worked.

Cancer vaccine hunt makes progress, finally

Moderna already demonstrated its capacity for developing and manufacturing mRNA vaccines. It had been working on vaccines for cancer and infectious diseases for more than a decade when the coronavirus pandemic hit, prompting the company to pivot to developing a Covid shot that, along with a similar one developed by Pfizer Inc. and BioNTech, became the first widespread commercial application of mRNA technology.

Building a successful cancer vaccine will be much more difficult. Moderna starts with a biopsy of a patient’s tumor, which it then sequences and uses artificial intelligence to pick out the mutations likely allowing the cancer to thrive. Then, mRNAs encoded for the most relevant cancer-driving proteins are packed inside a delivery system called a lipid nanoparticle, the same kind of delivery method used in Covid vaccines.

From tumor biopsy to first vaccine dose, the process can take between eight and 10 weeks, says Moderna Chief Medical Officer Paul Burton. Repeating this over and over for each patient enrolled in the clinical trial was a major undertaking, he adds.

Now imagine doing that for a commercial drug earmarked for thousands rather than for a few hundred people in a controlled study. There are nearly 100,000 cases of melanoma annually in the US, according to the American Cancer Society. While most cases are curable when detected early, more than 7,500 people die every year of the disease.

Bringing down the “needle-to-needle” time between biopsy and immunization will be critical to ensuring the treatment isn’t just promising, but practical and accessible to anyone who might benefit from it. One way to speed things up would be to establish regional hubs to quickly process biopsies.

Another measure that eventually could accelerate the development of the melanoma vaccine would be to simplify the vaccine’s components. Currently, the vaccine targets a laundry list of 34 mutated proteins to garner the full effect. It would be worth figuring out whether returns start to diminish after, say, 15 or 20 proteins.

Researchers also would like to understand whether certain types of tumors rely on common drivers that, if discovered, could be the foundation for a more broadly designed vaccine that could have some tailor-made components sprinkled in.

Burton says that Moderna so far hasn’t seen any common drivers that could help generalize components of the vaccine, but that data are limited — and the hope is that some clues might emerge as the vaccine is used over the long term and many more people are treated.

Scientists also still need to study the best way to use this vaccine for long-term suppression of cancer, considering, for example, whether people need to continue taking it every three weeks for life, or if they can get by with a periodic boost. And if someone’s disease progresses, does the vaccine itself need to be retooled to match new mutations that might have cropped up?

Perhaps the biggest question right now is whether the effect seen in melanoma can be extended to other types of cancer. Moderna Chief Executive Officer Stephane Bancel told CNBC recently that the company is moving aggressively into Phase 3 studies with the belief that “anywhere Keytruda works, this should work.”

Keytruda, meanwhile, is approved to treat a long list of cancers beyond melanoma—so many, in fact, that it’s expected to bring in more than $24 billion in sales in 2023. Bancel suggested that the vaccine might even make possible responses in tumors where Keytruda has failed, either on its own or by acting synergistically with Merck’s drug.

That’s an optimistic claim—worth studying, but a feat that has eluded other cancer immunotherapies. Melanoma is what’s known as a “hot” tumor, or one that features many mutations and has plenty of immune cells milling about, ready to be pushed into doing their cancer-killing job. It’s reasonable to be hopeful that Moderna’s vaccine could extend Keytruda’s benefits in other hot tumors, such as those found in lung cancer.

But “cold” tumors, or ones without that crowd of immune cells ready to be activated, are a much tougher proposition. In an earlier small study of the Moderna vaccine in solid tumors, for example, none of the patients with colon cancer — a notoriously “cold” tumor — responded, Bauman says.

Another immense challenge is the very high likely cost of a personalized therapy on top of Keytruda, which on its own carries a list price of around $185,000 per year. The only upside to that hefty price tag is that the companies will be motivated to answer these questions as quickly as possible. Indeed, Bancel has said that Moderna plans to aggressively invest in cancer.

All that money flowing into Moderna’s cancer vaccine will teach the field not just about that one product, but how to design, test and use other ones. Let’s hope that’s the catalyst for the true cancer vaccine revolution, one that could convert cancer from a potentially lethal illness into a chronic, stable disease.

Read  more at-https://bit.ly/3GuFwe8

Categories
COVID-19 Government Guidelines Medical Equipments Medical Updates Medicine & Health

What is POTS; experts on symptoms of post Covid condition that causes heart palpitations

Many post Covid patients who mistakenly believe their rapid heartbeat is due to anxiety could be suffering from POTS. Know all the symptoms of the disorder.

Do you experience dizzinessfatigue or rapid heart beat while getting up from the bed or a chair after prolonged sitting? You could be suffering from Postural orthostatic tachycardia syndrome (POTS), a condition that causes the heart to beat faster than usual. Our autonomic nervous system or the part of the nervous system that controls muscles of internal organs such as heart, blood vessels, lungs, stomach, and intestines is usually tasked with maintaining a healthy balance between heart rate and blood pressure to keep the blood flowing at a regular pace. In POTS, however, this function gets disrupted. Many post Covid patients who may mistakenly believe their rapid heartbeat is due to anxiety could be suffering from POTS.

WHAT IS POTS

“When you move from laying down or sitting to standing up, POTS, a disorder that causes your heart to beat more quickly than usual, can occur,” says Dr. Rajiv Dang, Senior Director and HOD – Internal Medicine and Medical Director, Max Hospital Gurugram.

What is POTS; experts on symptoms of post Covid condition that causes heart palpitations

SYMPTOMS OF POTS

– Dizziness or lightheadedness after prolonged standing or sitting

– Fainting

– heart palpitations

– fatigue or exhaustion

– Feeling anxious

– Excessive sweating

– Headache

– Shortness of breath

POTS symptoms can worsen on hot days, doing strenuous activities or during menstruation.

HOW POTS IS A LONG COVID MANIFESTATIOn

“We have what is basically one of the manifestations of long Covid syndrome, Postural Orthostatic Tachycardia Syndrome. People visit the doctor with mild palpitations and a lot of patients feel that it is anxiety but it may not be anxiety. It may be a symptom of the long Covid called POTS, the palpitations and so on, but it may remain for two months, six months or maybe more but it settles over a period of time. You may treat each patient differently according to their symptoms,” says Dr Vasant Nagvekar, co-director of infectious disease at Sir HN Reliance Foundation Hospital.

No matter what posture your body is in, your autonomic nervous system normally maintains a healthy balance between your heart rate and blood pressure to keep your blood flowing at a regular pace.

“If you have POTS, your body is unable to balance the reaction of your heart rate and blood vessel constriction (squeezing). This signifies that your body is unable to maintain a constant and stable blood pressure level,” says Dr Dang.

“There is no hard evidence of the connection between Covid and POTS but we have witnessed that post Covid patients come with this issue and it could be an effect of long Covid,” says Dr Nagvekar.

Read more at-https://bit.ly/3jybP2V